Introduction
DNA replication is a most central and fundamental biological process required for all organisms and, therefore, finely regulated primarily by a series of DNA polymerases. However, their fidelity has an intrinsic limit. Mutation rates on the genome are nevertheless suppressed to an extremely low level in each organism. The vast reduction of replication errors is chiefly made possible by two molecular mechanisms: (A) proofreading (PR) by 3′ exonuclease activities in the polymerase complexes and (B) postreplicative DNA mismatch repair (MMR) [1] . Indeed, loss of either or both mechanisms has been shown to lead to a remarkable induction of point mutations on the genome in genetically modified animals [2, 3] . Furthermore, MMR defects are frequently associated with human neoplastic diseases. In particular, germline mutations in MMR genes are known to lead to an inherited cancer predisposition, i.e. Lynch syndrome (LS) [4, 5] . Replication errors caused by polymerases largely consist of (a) base mismatches derived from nucleotide misincorporations and (b) misalignments on the repetitive sequences due to DNA polymerase 'slippage', which, if remain uncorrected, are fixed during subsequent replication as (a′) base substitutions and (b′) insertions/deletions (alias frameshifts), respectively. Both of the replication errors are a good substrate for MMR. Indeed, in MMR-defective E. coli stains such as mutS or MutL 'mutator', the frequencies not only of frameshifts but also of base substitutions are known to be elevated on the genome [6, 7] . Similarly, both base substitutions and frameshifts are increased also in a PR-defective mutator, dnaQ (mutD5) [8] . Thus, MMR and PR are the two major mechanisms counteracting the replication errors that suppress base substitutions and frameshift mutations on the genome, consequently guaranteeing the high fidelity of DNA replication.
The phenomenon of unstable repeat sequences in human tumours has initially been reported as microsatellite instability (MSI). Microsatellites are a class of short tandem repeats (STRs) comprising short reiterative motifs ranging from one to six-bp and evolutionally conserved from yeasts to humans. Numerous microsatellites have been mapped throughout the human genome. Although being highly polymorphic in human populations, they are stable during the life span of the individual. Somatic instability of microsatellites, i.e. MSI, has first been reported in tumours occurring in LS patients [9] . Long repetitive sequences such as microsatellites are particularly prone to polymerase slippage and readily form strand misalignments. Since germline mutations in MMR genes were found in LS kindred [4, 5] , the MSI phenomenon was instantly and straightforwardly connected to defective MMR, in view of the above discussed mechanisms. However, several discrepancies have been pointed out in microsatellite-unstable human neoplasms. First of all, the MSI + phenotype is not uniform in human tumours. The 1997 National Cancer Institute (NCI) workshop recommended that MSI-positive tumours should be classified into two phenotypes, i.e. MSI-H (high, ≥ 30-40%) and -L (low, < 30-40%), according to the frequencies of changes in a defined set of microsatellite markers [10] . MSI-H has been regarded as an authentic MMR-defective MSI phenotype, because, in LS tumours, microsatellite alterations are frequent genome-widely and often observed in many of selected markers. However, point mutations in the TP53, KRAS and APC genes, which are most frequently mutated and therefore regarded as classical and major oncogenic genes in human colorectal cancer [11] , are extremely rare in tumours with the MSI-H phenotype [12] . Accordingly, two mutually exclusive pathways have been hypothesised in human colorectal tumourigenesis (see Discussion). Recent NGS-based approaches have indeed revealed that mutations including base substitutions frequently occur on the genomes of MSI-H tumours [13, 14] . However, the paucity of major oncogenic gene mutations is enigmatic, particularly in view of the facts that base substitution-type mutations effectively affect the genes and that base substitutions and frameshifts are equally frequent in MMR-defective cells, as discussed above. On the one hand, we have previously reported two qualitatively distinct modes of dinucleotide microsatellite alterations in human tumours, i.e. Type A and Type B [15] . Type A alterations are defined as length changes within 6-bp (i.e. three repeat units), and Type B as more drastic modifications over 6-bp. Both types of instability are observed in various human neoplasms [16] [17] [18] [19] [20] , and microsatellite alterations typical in MSI-H tumours, including those occurring in LS individuals, are Type B [18] . Intriguingly, TP53 mutations, the majority of which are base substitutions in general, were strongly associated with Type A instability in colorectal cancer [15] . Thus, in contrast to MSI-H tumours, both of repeat frameshifts and TP53 mutations are frequent and concurrent in tumours exhibiting Type A MSI. Forward genetics such as gene targeting is one deductive and important approach to the relationship between gene functions and phenotypes. A number of MMR gene knockout (KO) mice has thus far been engineered and reported [21] . Indeed, tumours frequently occur in these animals as in LS patients. However, the variety of neoplasms is far different between them. In addition, the variety of mutated genes is also different. More importantly, tumours occurring in these animals do not exhibit microsatellite changes typical in MSI-H tumours. We have instead observed Type A alterations in MMR-defective mouse cells and tumours occurring in the KO animals [15] , which may more strongly and directly connect Type A instability to MMR defects. Further discrepancies have been observed in MMR gene KO mouse cells. Tolerance to alkylating agents has been established as an important phenotype of MMR-defective human cells [22] . However, it has been shown that MMR-defective mouse cells do not exhibit a similar level of resistance [23] , which may suggest that there might be a difference either in their repair activities or in cell death signalling. Indeed, these two functional aspects of the MMR system are known to be segregated in some MMR gene mutant organisms. MSH2 G674A-mutant mouse cells have been shown to lack MMR activities whereas being still sensitive to alkylating agents [24] . The above line of evidence has strongly prompted us to a priori introduce MMR gene mutations into human cells and to test their effects on the genome and the cell. Coincidentally, human MSH2 G674 mutations have been reported in LS kindred and established as deleterious and, therefore, pathogenic [24] [25] [26] . In the present study, we have introduced these pathogenic MSH2 mutations into HeLa cells, using the recently developed genome editing technique, CRISPR/Cas9 system [27] [28] [29] . The results obtained clearly suggest the complexities in the repeat dynamics on the human genome. The established MSH2-mutant clones exhibited remarkable alkylating agent-tolerance and E coli 'mutator'-like phenotypes with elevated point mutation frequencies, both of which imply that the cells are unequivocally MMRdefective. Nevertheless, microsatellite sequences were not markedly destabilised as in tumours occurring in LS individuals. Our findings suggest that, in addition to defective MMR, previously unrecognised molecular mechanisms may underlie repeat destabilisation in human neoplasms.
Materials and methods

Plasmids
The genome editing vector, pSpCas9(BB)-2A-Puro (pX459, Addgene plasmid # 48139), was provided by Addgene (Cambridge, MA, USA). The guide RNA sequence for human MSH2, gRNA1 (Fig. 1C) , was designed using CRISPRdirect and CRISPR Design Tool and subcloned into pX459 using the BbsI site. The cloned guide RNA sequence was confirmed by DNA sequencing using two primers, 5′-CGTTTGTAGGCCCC AATATGG and 5′-CCCATATTGGGGCCTACA.
primer, MSH2-1R, 5′-TTCCAACATTTCAGCCATGA) were subcloned into a plasmid, using TOPO ® TA Cloning ® Kit for Sequencing (Invitrogen, Thermo Fisher Scientific), and separately analysed. From ten to twelve plasmid clones were sequenced to determine the allelotype of each clone (see Table 1 ).
DNA sequencing
Target sequences were amplified by PCR using MightyAmp™ DNA Polymerase or TaKaRa EX Taq (Takara Bio Inc. Kusatsu, Japan). PCR products were used as a template for cycle sequencing reactions using BigDye™ Terminator v3.1 or v1.1 Cycle Sequencing Kit (Applied Biosystems, Thermo Fisher Scientific), following the manufacturer's 
a ) The numbers of plasmid clones identified in allele-specific sequencing are indicated in the prentheses. b ) See data in Fig. 2 . c ) In HeLa cells, chromosome 2 is trisomic (see text). d ) One allele has undegone 163-bp deletion encompassing the initiation codon in exon1, remaining one copy of the BAT26 sequence in intron5 (see Fig. 6 ). The other two are suggeted to be more largely deleted in the region from exon1 to intron5, possibly due to pop-out recombination. e ) One allele is suggetsed to include a large deletion (see text). protocol.
DNA fragment analysis
Microsatellite analysis using fluorescence-labelled primers and an automated DNA sequencer has been described in detail [30] . Briefly, five human dinucleotide microsatellites, D2S123, D5S107, D10S197, D11S904, D13S175 and one mononucleotide microsatellite, BAT26 (forward primer, 5′-GTGACTACTTTTGACTTCAGCC; reverse primer, 5′-GAACCAATCAACATTTTTAACCC), were amplified by PCR in each genomic DNA sample. For BAT26, an ssODN with the sequence, 5′-TGCAGTTTGAACTGACTACTTTTGACTTCAGCCAGTATATGAAATTG GATATTGCAGCAGTCAGAGCCCTTAACCTTTTTCAGGTAAAAAAAAAA AAAAAAAAAAAAAAAAGGGTTAAAAATGTTGATTGGTTAA, was used as a 'calibrator' template (see Fig. 6 ). For the TGFBR2 locus, a set of PCR primers (forward, 5′-TTTGCCATGACCCCAAGCTCC; reverse, 5′-GAAG ATGATGTTGTCATTGC) and another ssODN for 'calibrator', 5′-GAAG ATGATGTTGTCATTGCACTCATCAGAGCTACAGGAACACATGAAGAAA GTCTCACCAGGCTTTTTTTTTTCCTTCATAATGCACTTTGGAGAAGCAG CATCCTTCCAGAATAAAGTCATGGTAGGGGAGCTTGGGGTCATGGC AAA, were used (see Fig. 7 ). PCR reactions were done using TaKaRa Taq (Takara Bio Inc. Kusatsu, Japan) and primers labelled with a fluorescent dye, 6-FAM (6-carboxyfluorescein) or HEX (6-carboxy-2′, 4′, 7′, 4, 7, hexachloro-fluorescein). To compare electrophoretic profiles between two samples, two PCR products independently labelled with 6-FAM or HEX were mixed and loaded onto the ABI310 sequencer (Applied Biosystems, Thermo Fisher Scientific). Data were processed using the GeneScan software (Applied Biosystems, Thermo Fisher Scientific).
Immunoblotting
Cells (1.0 ×10 6 ) were directly lysed in 100 μl of 2 × SDS sample buffer (62.5 mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 25% (w/v) Glycerol, 0.01% (w/v) Bromophenol Blue, 5% (v/v) 2-Melcaptoethanol) (BioRad, Hercules, CA, USA), incubated at 100°C for 10 min and chilled on ice. Cell lysates (10 μl) were subjected to SDS-polyacrylamide gel electrophoresis, and proteins were transferred onto PVDF membranes with 0.2 µm pore size (Bio-Rad, Hercules, CA, USA). After blocking with 2% skimmed milk (Nacalai Tesque, Kyoto, Japan) in PBS containing 0.1% tween 20, the membranes were reacted with the following primary antibodies: anti-MSH2 mouse monoclonal antibody FE11(Calbiochem, San Diego, CA, USA), anti-MSH6 rabbit monoclonal antibody EPR3946 (Abcam PLC, Cambridge, UK) and anti-β-actin mouse monoclonal antibody AC-15 (Sigma-Aldrich). The membranes were further reacted with an appropriately diluted anti-mouse or antirabbit IgG conjugated with horseradish peroxidase (HRP) (GE Healthcare, Chicago, IL, USA), followed by reaction with Luminata™ Forte HRP substrate (Merck Millipore, Burlington, MA, USA). Luminescent signals were visualized by ChemiDoc™ MP system (BioRad).
Mutation frequency
Cells were cultured in D-MEM containing 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin and HAT supplement (0.1 mM hypoxanthine, 0.4 μM aminopterin and 16 μM thymidine) (Gibco, Thermo Fisher Scientific) in order to eliminate HPRT-mutated cells. Cells were then cultured in the same media without aminopterin. Cells (1.0 ×10 6 ) were replated on a 100 mm dish and grown to about 2 × 10 7 cells. Exponentially growing cells were divided into ten 100 mm dishes at the density of 2 × 10 6 cells/dish and cultured in the media supplemented with 10 μM 6-thioguanine for 10 days to form colonies. In order to determine the plating efficiency, 200 cells were inoculated onto a 60 mm dish. Formed colonies were fixed with 3.7% formaldehyde (Nacalai Tesque), stained with 0.1% crystal violet (Wako Pure Chemical Corporation, Osaka, Japan) and counted. Mutation frequency was calculated from the number of resistant colonies and the plating efficiency.
Cellular MNU-resistance
Two hundred cells were plated onto a 60 mm dish one day before drug treatment. Cells were then treated with various concentration of MNU in D-MEM containing 20 mM HEPES-HCl (pH 6.0) for 1 h at 37°C and 5% CO 2 . After replacing the medium including MNU, cells were washed once with PBS and further cultured for 10 days. Formed colonies were fixed and stained as described above. Survival rates were calculated from the number of resistant colonies.
Flow cytometry
Cells were trypsinised and suspended in PBS. The cell suspensions were mixed with an equal volume of the Muse ® Annexin V and Dead
Cell Assay Kit reagent (Merck Millipore), incubated for 20 min at room temperature in a dark place and then assayed using of Muse ® Cell
Analyzer (Merck Millipore), according to the manufacturer's protocol.
Results
Introduction of pathogenic MSH2 mutations into HeLa cells by CRISPR/Cas9 system
The glycine at position 674 resides in Walker A motif in the ATPase domain of human MSH2 (Fig. 1A) . The substitution of the glycine to alanine leads to a defect of ATPase activity that is essential for its conformational change to form a sliding clamp on DNA and to interact with MutLα [31] . G674 mutations to other amino acids have also been reported in LS kindred [25, 26] . We have therefore introduced an ATPase-defective MSH2 mutation, G674A, and two LS-related MSH2 mutations, G674D and G674R, into HeLa cells, using the genome editing technique, CRISPR/Cas9 system. In order to introduce double strand breaks (DSBs) near the sequence encompassing G674, we designed the guide RNA, gRNA1 (Fig. 1C) . We also designed ssODNs used as repair templates to introduce the desired mutations during the process of homology-directed repair of DSBs induced by CRISPR/Cas9. In addition to the desired mutations, we also introduced a synonymous base substitution to create a diagnostic restriction site for detecting the desired mutations (Fig. 1B) . HeLa cells were transfected with a plasmid vector encoding gRNA1 and ssODNs, followed by puromycin selection. Transfectants were then subjected to limiting dilution in order to obtain single colonies. To select candidate clones, we performed allele-specific PCR using primers specific for each desired mutation, and initially obtained 8, 7, and 4 clones for the G674A, G674R, and G674D genotypes, respectively. We further analysed the selected clones using RFLP assay, in order to confirm the genotypes. Finally, allele-specific DNA sequencing has confirmed each genotype in the candidates (Fig. 1D) , and, in addition, variously inactivated alleles including 1-bp insertions and deletions with various sizes, all of which occurred around the Cas9 cutting site (see Supplementary Fig. 1 ), were also noted at this trisomic locus [32] . All the RFLP-positive clones were successfully confirmed to carry the desired mutations. In one G674R clone, we detected only G674R allele. However, a PCR analysis detected a large deletion in the genomic context, suggesting that two of the three alleles are G674R in this clone (data not shown). Neither did we obtain clones homozygous for the mutated alleles nor heterozygotes including the wild type allele. The overall efficiencies of selection were as follows: G674R, 6.3% (6 / 96); G674D, 2.1% (2 / 92); G674A, 3.4% (6 / 172). We have finally selected six MSH2-mutant HeLa clones for the three genotypes. The designation and the allelotype of each clone are summarised in Table 1 . The MSH2-KO HeLa clone (Hayashida G et al. unpublished data) , in which all the MSH2 alleles are homozygously knocked out, was also used as a positive control.
The expression levels of mutant MSH2 proteins were observed by immunoblotting analysis in lysates of each mutant clone, together with the titration of the wild type HeLa lysate ( Fig. 2A) . We also monitored the expression levels of MSH6, because MSH6 is a dimerization partner and stabilised by MSH2 proteins through its interaction. Quantification of the data has revealed that the expression levels of G674R and G674D MSH2 were extremely low, whereas G674A MSH2 were expressed approximately at 1/3 of the wild type level. The expression levels of MSH6 were highly parallel to those of mutant MSH2 proteins.
One of the most remarkable cellular phenotype of MMR-defective human cells is resistance to alkylating agents. In 1993, Karran and colleagues [22] first showed that MMR deficiency confers an extreme alkylating agent-tolerance on human cells defective in O 6 -methylguanine-DNA methyltransferase (MGMT). In this study, we therefore employed an MGMT-defective HeLa subline, HeLa-MR [33] . In order to confirm that the above genome editing has indeed abrogated MMR functions in each of the established clones, we tested whether they exhibit resistance to alkylating agents. For this purpose, we performed clonogenic survival assay to examine the sensitivity of each clone to the killing effects of N-methyl-N-nitrosourea (MNU). All the MSH2 G674 mutant clones showed an unequivocal tolerance to MNU as did the MSH2-KO clone, whereas the survival of the parental wild type HeLa cells drastically decreased even at low concentrations of MNU (Fig. 3A) . The cell cycles analysis revealed that MNU-treatment clearly induced cell cycle arrest at G2 phase in MNU-sensitive MMR-proficient HeLa cells, but not in MNU-resistant MSH2-defective clones. (Fig. 3B and Supplementary Fig. 2 ). Consistent with the tolerance to MNU, the G674 mutant clones failed to induce G2 arrest after MNU-treatment ( Fig. 3B and Supplementary Fig. 2 ). These observations are highly concordant with MMR-deficiency in these newly established HeLa clones.
Genomic destabilisation in HeLa cells carrying MSH2 G674 mutations
As discussed above, replication errors caused by DNA polymerases are largely comprised of base mismatches and repeat misalignments, which, if uncorrected, lead to base substitutions and repeat length changes, respectively. To evaluate the ability of the MSH2-mutant clones for correcting these replication errors, we first analysed the spontaneous mutation frequency in their genomes using the HPRT locus as a marker. As expected, the mutation frequencies in the MSH2 G674 mutant clones were uniformly elevated to the level of the MSH2-KO clone, whereas being suppressed to an extremely low level in the parental wild type HeLa clone (Fig. 4) .
In addition to point mutations occurring in the genes, we next examined the stability of microsatellite sequences in these MSH2-mutant HeLa clones. When the microsatellite stability is examined using established cell lines, the standard approach is to isolate several independently grown subclones and to compare the microsatellite lengths among them, since each subclone undergoes an independent and sufficiently long history of DNA replication and, consequently, changes accumulated in DNA replication are maximised and readily detected in this approach [34] . We have therefore isolated several subclones from each HeLa clone. As a technique to analyse microsatellite length changes, our unique assay system, HRFMA [30] , was employed. In this technique, a number of methodological improvements have been made [30] . In particular, the electrophoretic profiles of PCR-amplified microsatellite sequences are maximally simplified and, therefore, highly reproducible, which enables us to sensitively detect the appearance of new alleles with different repeat lengths, however minor and subtle they may be. The shift in the migration position of electrophoresed DNA fragments is also sensitively detected, because each electrophoresis is standardised by co-electrophoresing size markers and sizing methods are carefully chosen. Using this technique, we first approached the stability of dinucleotide microsatellites in the MSH2-mutant HeLa clones. Among numerous dinucleotide microsatellites mapped throughout the human genome, we previously examined the stability of a set of dinucleotide microsatellites in several established human cell lines that harbour known mutations in MMR genes [34] . Although the selected microsatellite markers were all sensitively destabilised in response to the MMR-defective phenotypes of the cells, the most sensitive marker was D10S197. We therefore analysed D10S197 sequences in the HeLa clones (Fig. 5) . Due to slippage of thermostable polymerases, PCR-amplification of a dinucleotide microsatellite sequence yields a set of three DNA fragments with different repeat unit numbers, and electrophoresis resolves them as a cluster of three peaks. Since microsatellites are highly polymorphic in human populations and, therefore, often heterozygous in the repeat unit number, two clusters, which sometimes separate or overlap, are detected in many cases. Needless to say, the complete homozygous allelotypes form a single cluster of peaks. Thus, the electrophoretic profiles of microsatellite PCR products theoretically comprises a combination of two clusters of peaks [35] . In the parental wild type line, HeLa, two clusters of peaks were detected in the electrophoretic profiles (Fig. 5A) . However, the peak heights are different between them, and shorter peaks are approximately two times higher than the longer cluster, which derives from trisomy of chromosome 10 in HeLa cells [32] . More remarkably, these electrophoretic profiles were completely identical among the isolated subclones (Fig. 5A) , which implies that the dinucleotide microsatellite is invariable in this cell line. In the MSH2-KO HeLa clone, one allele was apparently longer than the 168-bp allele detected in the parental HeLa cells, which may be due to an independent and long history of culture of this clone. However, more importantly, this 174-bp allele was obviously variable and fluctuated in its length (Fig. 5B) . Some clusters of peaks included several alleles with different repeat numbers, which provided new peaks (see arrows in Fig. 5B ). In one subclone, the 160-bp allele was also shifted, and, consequently, it appears as if the allele was heterozygously duplicated. Thus, dinucleotide microsatellites were indeed unstable in the MSH2-KO HeLa clone. We next analysed the newly established HeLa clones with MSH2 G674 mutations. Microsatellite length alterations were observed also in these clones. They all were similarly heterozygous for D10S197, and two alleles, 160 and 168-bp, were detected as in the wild type clone (Fig. 5C and D) . In some subclones, the alleles were destabilised, and new peaks were noted (see arrows in Fig. 5C and D) . However, the overall frequencies of microsatellite-unstable subclones (1/6 in RD03; 0/6 in RH07; 2/6 in DA02; 4/6 in DC08; mean, 29%) were not very high compared to that in the MSH2-KO clone (42%). These observations suggest that, in the HeLa clones with MSH2 G674 mutations, dinucleotide microsatellites are indeed variable, but that their destabilisation is relatively moderate. One important observation is that all the length changes detected here were within 6-bp, which implies that the MSI mode observed in these clones was uniformly Type A.
Next to dinucleotide microsatellites, we also analysed mononucleotide repeats in these clones. Although not being widely recognised, mononucleotide repeats may be more variable and more complexly regulated than dinucleotide repeat sequences (see Discussion). We have therefore introduced into our system a control designated as 'calibrator', which is a PCR-amplified product of an artificially synthesised ssODN with a sequence completely identical to the target context and a known repeat number. 'Calibrator' is also labelled with a different fluorescent dye and co-electrophoresed with genomic PCR products (Fig. 6A) . The BAT26 sequence has been chosen as a target, since this mononucleotide microsatellite, located in intron 5 of the MSH2 locus in chromosome 2, has been established as a sensitive marker for microsatellite-unstable phenotypes of human tumours [36] [37] [38] . In HeLa cells, PCR-amplified BAT26 sequences provide a complex electrophoretic profile, which may be comprised of mutually overlapped three clusters of peaks, each being derived from the trisomic alleles in chromosome 2 (Fig. 6A) . In the wild type HeLa clone, all the isolated subclones showed completely identical profiles in electrophoresis, which implies that the mononucleotide microsatellite is not variable in the wild type background (Fig. 6B) . In the MSH2-KO clone, a different electrophoretic profile was observed (Fig. 6C) . There was only one cluster of peaks derived from an allele, which may be compatible with our previous observations suggesting that two of the three copies of the local sequence may have been lost by possible pop-up G. Hayashida, et al. Experimental Cell Research 377 (2019) [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] recombination during the processes of gene targeting in this clone (data not shown). The residual 116-bp allele was, however, not markedly destabilised. The ratios among peaks are indeed different in some subclones, which may suggest that there were subpopulations with different repeat lengths. However, neither a shift of peak clusters nor an appearance of new peaks was observed (Fig. 6C ). These observations may suggest that BAT26 mononucleotide microsatellite may indeed be destabilised in the MSH2-KO HeLa clone, but that its instability is relatively limited, which may be in contrast with our observations in dinucleotide microsatellites. Intriguingly, the instability of BAT26 sequence in the MSH2 G674-mutant clones was more limited than that in the MSH2-KO clone (Fig. 6D) . The observed electrophoretic profiles were almost identical to those in the wild type clone, with an exception that the highest peaks were shifted in two subclones. Thus, BAT26 microsatellite was not markedly destabilised both in the MSH2-KO and the MSH2 G674-mutant clones.
Another established mononucleotide marker for microsatellite-unstable phonotypes is the polyadenine run in the TGFBR2 gene [39, 40] .
This repetitive local sequence is comprised of ten adenines in the reference genome and, surprisingly, located in the centre of the ORF. It has been frequently reported in the literature that this repetitive sequence is destabilised in human tumours with microsatellite-unstable, i.e. MSI-H, phenotypes. In many reports in the literature, Sanger sequencing has been employed to approach its alterations. However, thermostable polymerases used for PCR frequently slip on a mononucleotide run, adding or deleting one or more nucleotides, and, consequently, often cause artefacts similar to frameshift mutations. Therefore, we here employed DNA fragment analysis, i.e. HRFMA, with 26 , is labelled with 6FAM and co-electrophoresed as a control with HEX-labelled genomic PCR products (indicated in green). Electrophoretic profiles were similarly analysed in HRFMA. In HeLa cells, the basic electrophoretic profile of amplified genomic BAT26 sequences is a superimposition of three independently amplified alleles, 116, 117 and 120-bp (each indicated in green), which derive from trisomy of chromosome 2. (B) In the wild type HeLa subclones, genomic BAT26 sequences were similarly analysed as in 'calibrators'. We have designed the system according to the local reference sequence, and the calibrator contained ten adenines, (A) 10 , in the run (Fig. 7A) . In the analyses of the wild type HeLa clone, both of the highest genomic peaks and the calibrator peaks invariably indicated 146-bp in all the isolated subclones (Fig. 7B) , which implies that the HeLa clone is homozygous for (A) 10 in this possible disomic TGFBR2 locus [32] . Surprisingly, the completely identical profiles have been obtained in both the MSH2-KO (Fig. 7C) and the MSH2 G674-mutatnt (Fig. 7D) subclones, which may suggest that the polyadenine run is not destabilised in HeLa cells with the MSH2-defective phenotypes, either by a complete loss of the gene or by an introduction of established pathogenic mutations reported in LS patients. We have also analysed the local sequence using the classical Sanger technique. Although minor artefactual frameshift mutations were observed, results obtained were completely identical in all the HeLa clones analysed (data not shown), which indicates that the local sequence is not different among the clones, consequently confirming the above results obtained using DNA fragment analysis.
Discussion
Genome-edited MSH2-mutant HeLa cells
Using the established genome editing technique, CRISPR/Cas9 system, we have introduced mutations into G674 position in the essential ATPase domain of human MSH2 in HeLa cells and characterised the established mutant clones. All the MSH2 G674 mutant clones showed deficiencies both in apoptosis induction by the exposure to alkylating agents and in suppression of spontaneous mutations on the genome, which implies that the established clones are unequivocally MMR-defective. These observations may also suggest that the repair function is in fact inseparable from cell death signalling induced by alkylating agents in human cells, which may also be parallel to our recent observation that the expression of MSH2 G674A cDNA in MSH2-KO clone failed to restore apoptosis induction as well as repair activities (Hayashida G et al. unpublished data) . In G674R and G674D clones, we observed extremely low expression levels of the mutant MSH2 proteins, which suggests that the quantity rather than the quality of the mutant proteins may cause MMR defects in these clones and also in tumour cells occurring in LS patients with the mutations. Thus, the established HeLa clones of all the three mutant genotypes clearly exhibited MMRdefective phenotypes.
Genomic instability in MSH2-mutant HeLa cells
The genomic instability observed here in the MSH2-mutant HeLa clones clearly had two contrary aspects. The mutation frequency determined in the HPRT locus was significantly elevated in these clones, which implies that point mutations frequently occur on their genomes and is highly consistent with their defects in MMR. On the other hand, destabilisation of microsatellites was not remarkable. The instability was relatively moderate in dinucleotide microsatellites and not evident in mononucleotide microsatellites. These findings were consistent throughout the MSH2-defective clones. One important finding in the present study is that all the observed alterations in dinucleotide microsatellites were uniformly Type A. In other words, the microsatellite length changes, i.e. insertions or deletions, were always within 6-bp. We observed no more drastic Type B changes typical in MSI-H tumours, which involve large insertions over 6-bp and sometimes appear as if a 'third' allele is present. These findings confirm our previous observations that there are two qualitatively distinct modes of destabilisation in dinucleotide microsatellites, and that defective MMR is necessary and sufficient for Type A alterations but not for Type B [15] . Our observations thus suggest that the Type A mode of MSI is a direct consequence of defective MMR, and that Type B, despite being the more generally acknowledged mode of MSI, may require previously unrecognised and additional molecular abnormalities. Mononucleotide microsatellites were generally more stable in the MMR-defective HeLa clones. The (A) 10 run in the TGFBR2 gene was completely stable in the clones, whereas the BAT26 sequence containing the (A) 26 run was suggested to be moderately destabilised in some subclones. The relative stability in mononucleotide repeats may suggest additional repair mechanisms for them. Considering that polymerase slippage events obviously depends on the repeat length and may be more frequent in mononucleotide repeats, the repeat sequence stability might be in a complex balance between their variability and repairability. Intriguingly, mononucleotide microsatellites often exhibit Type B mode large insertions in MSI-H tumours, and, therefore, are widely used as sensitive makers for the diagnosis of MSI-H [36] [37] [38] . However, in the MMRdefective HeLa clones, no Type B alterations were observed in the most established mononucleotide microsatellite, BAT26.
Repetitive DNA sequences such as microsatellites may be a hotspot for various replication errors including polymerase slippage and might therefore be more complexly maintained than hitherto hypothesised. Slippage model has been proposed to solely explain their destabilisation. However, one slippage event theoretically leads to a gain of one repeat unit and occurs equally both in the parental and daughter strands. Therefore, Type B mode large insertions typical in MSI-H tumours are not readily explicable. In one of our previous studies, we cultured MSH2-KO mouse cells for a long (more than 80 passages) period and analysed their microsatellites. However, detected alterations were all within 6-bp, i.e. Type A. Several molecular mechanisms have in fact been hypothesised to explain repeat expansion in eukaryotic cells. In addition to polymerase slippage, failure in 3′-'flap' processing has also been pointed out. The 3′ ends of Okazaki fragments often form flaplike structures, which, if uncorrected, lead to insertion mutations particularly in repeat sequences. Indeed, trinucleotide repeats are known to be markedly expanded in yeast mutants defective in the flap endonuclease gene, RAD27 [41, 42] , although defects in the mammalian counterpart of the gene, FEN1, have not yet been known in human populations. The drastic repeat alterations in Type B MSI may be more consistent with more dynamic events such as DNA recombination (gene conversion). Recombinational model for repeat expansion has indeed been discussed, particularly in connection to human triplet repeat diseases [43] . On this recombinational model, defective MMR might not necessarily be an essential but a promoting and, consequently, highly coincidental factor, because MMR also reacts strand misalignments formed in recombination and functions as a gatekeeper against incorrect strand crossing-over. Furthermore, destabilisation mechanisms may differ depending on the structure of repeat units. The initial recognition complexes in MMR, i.e. MutSα and MutSβ, differentially bind to repeat misalignments: the former chiefly binds to loop-outs with from one to three bases, whereas the latter to those with two and more bases. Moreover, in view of the structure of the catalytic centre of 3′ exonuclease domains, one-base loop-outs may be a good substrate for PR, but those with two bases and more may not. Therefore, mono-, di-, and tri-nucleotide repeat sequences may be in fact maintained by several different systems with different intensiveness, although their role divisions remain unclear. Thus, molecular mechanisms underlying microsatellite alterations may be oversimplified and, in fact, more complex than generally recognised. Particularly, connection between Type B MSI and recombinational repair may warrant attention.
In the context of tumourigenesis theories
MSI may thus not be exclusively associated with defective MMR. The complexity in the MSI phenomenon may cast a shadow on carcinogenesis theories and its reliability as a biomarker in cancer treatment. In the classical and canonical theory of colorectal tumourigensis, point mutations activate oncogenes and inactivate tumour suppressors in concert with chromosomal instability causing loss of heterozygosity (LOH) at hemi-mutated loci.
Step-by-step alterations of these genes are thought to lead cells to tumourigenesis in human colorectal cancer [11] . However, as discussed above, point mutations in these major oncogenic genes, such as TP53, KRAS or APC, are extremely rare in MSI-H tumours [12] . Therefore, microsatellite-unstable tumours have been excluded from the classical tumourigenesis pathway (i.e. 'CIN' (Chromosomal INstability) pathway) and, instead, another independent pathway (i.e. 'MIN' (Microsatellite INstability) pathway) has been proposed [44, 45] . The former classical pathway corresponds to the currently proposed 'consensus molecular subtype 2′ (CMS2) ('canonical'), and the latter to CMS1 ('microsatellite instability immune') [46, 47] . Tumourigenesis independent of the classical model is of particular interest. In MSI-H tumours, mutations have been pointed out in a limited number of particular genes such as TGFBR2, IGF2R, BAX, CASP5 etc [48] , which harbour mononucleotide runs within their ORFs and are functionally connected with cell growth or cell death. However, in our present study, TGFBR2 mutations were found neither in the HeLa clones with pathogenic MSH2 mutations nor in the MSH2-KO clone, which may suggest that TGFBR2 alterations are in fact not so tightly associated with defective MMR as has been expected. Mononucleotide repeats may in fact be rigorously maintained by both MMR and PR, and, therefore, defective MMR may not solely destabilise mononucleotide repeat sequences effectively, as discussed above. Tumourigenesis via the MIN pathway is still enigmatic.
In the clinical context
MSI, in the clinical context, is now regarded as an important biomarker in cancer treatment strategies, because antibodies against a cell surface antigen inhibiting anti-tumour immune responses, programmed death 1 (PD-1), or its ligands have been shown to be particularly effective in patients with tumours exhibiting MSI-H [49] . MSI testing is now prerequisite for some anti-PD-1 agents. This reasoning is primarily based on the hypothesis that 'non-self' immunogenic antigens may be coded by somatic mutations derived from defective MMR [49] . However, the relationship between defective MMR and MSI-H is not straightforward, as shown in our present study. Further studies may be required to more firmly establish the MSI phenomenon as a biomarker for the anti-PD-1 therapy. Defective MMR has in fact been a longstanding candidate as a biomarker for anti-neoplastic chemotherapy. It has been established in vitro that defective MMR confer on cells the resistance to various anticancer drugs including not only alkylating agents but also more commonly used agents such as 5-fluorouracil (5-FU) [50, 51] . Although numerous clinical studies have approached the association between the MSI-H phenotype and 5-FU resistance in colorectal cancer patients, the results thus far reported are inconsistent and not conclusive [52] . On the one hand, we have observed Type A MSI in various human neoplasms and found its significant association with drug resistance in several haematological malignancies [19, 20] , although the variety of used agents being different. Type A MSI may also be an effective biomarker for cancer patients treated with 5-FUbased and anti-PD-1 therapies. However, it is necessary to confirm its effectiveness clinically in sufficiently large cohorts, before concluding so. Precise assay techniques also need to be propagated, because Type A alterations are minor and more subtle than the widely acknowledged B mode microsatellites changes. More detailed studies are required to elucidate the bona fide dynamics of simple repeat sequences in human disease.
Conclusions
Using the CRISPR/Cas9 system, we have introduced LS kindredrelated pathogenic MSH2 mutations into HeLa cells. MSH2-mutant HeLa clones have been successfully obtained, and the established clones clearly exhibited MMR-defective phenotypes with alkylating agenttolerance and elevated mutation frequencies. However, in these clones, microsatellites were not markedly destabilised as in tumours occurring in LS patients. All the observed alterations were within one to several repeat units, as previously observed in tumours occurring in MMR gene knockout mice. These findings strongly confirm that defective MMR is not sufficient for the drastic microsatellite alterations that are generally observed in human tumours. Molecular mechanisms underlying microsatellite alterations in human neoplasms are obviously oversimplified. Our findings suggest that, in addition to defective MMR, previously unrecognised molecular mechanisms may underlie repeat destabilisation in human cells.
